APO Research
Talk to an analyst

APO RESEARCH · REPORT

FIC Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global FIC Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

29 December 2025190 pages

Choose your research edition.

Industry ResearchFIC Drugs Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal FIC Drugs Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal FIC Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal FIC Drugs Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal FIC Drugs Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global FIC Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for FIC Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for FIC Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for FIC Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for FIC Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of FIC Drugs include Agios, BMS, Boehringer Ingelheim, Dermavant Sciences, Genentech, Gilead, Immunocore, ImmunoGen and Mallinckrodt, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global FIC Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of FIC Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents FIC Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the FIC Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

FIC Drugs Segment by Company

Agios

BMS

Boehringer Ingelheim

Dermavant Sciences

Genentech

Gilead

Immunocore

ImmunoGen

Mallinckrodt

Marinus

Phathom

Polarean lmaging

Pfizer

Eli Lilly

Roche

Merck

Novartis

Johnson & Johnson

Sanofi

FIC Drugs Segment by Type

FIC Single-target Drugs

FIC Dual-target Drugs

FIC Drugs Segment by Application

Hospital

Clinic

Other

FIC Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global FIC Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of FIC Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of FIC Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the FIC Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of FIC Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of FIC Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of FIC Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. FIC Drugs Industry Trends Table 2. FIC Drugs Industry Drivers Table 3. FIC Drugs Industry Opportunities and Challenges Table 4. FIC Drugs Industry Restraints Table 5. Global FIC Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global FIC Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global FIC Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global FIC Drugs Sales Market Share by Manufacturers Table 9. Global FIC Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global FIC Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global FIC Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global FIC Drugs Manufacturers, Product Type & Application Table 13. Global FIC Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global FIC Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of FIC Single-target Drugs Table 17. Major Manufacturers of FIC Dual-target Drugs Table 18. Global FIC Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global FIC Drugs Sales by Type (2021-2026) & (K Units) Table 20. Global FIC Drugs Sales by Type (2027-2032) & (K Units) Table 21. Global FIC Drugs Sales Market Share by Type (2021-2026) Table 22. Global FIC Drugs Sales Market Share by Type (2027-2032) Table 23. Global FIC Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global FIC Drugs Revenue by Type (2021-2026) & (K Units) Table 25. Global FIC Drugs Revenue by Type (2027-2032) & (K Units) Table 26. Global FIC Drugs Revenue Market Share by Type (2021-2026) Table 27. Global FIC Drugs Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospital Table 29. Major Manufacturers of Clinic Table 30. Major Manufacturers of Other Table 31. Global FIC Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global FIC Drugs Sales by Application (2021-2026) & (K Units) Table 33. Global FIC Drugs Sales by Application (2027-2032) & (K Units) Table 34. Global FIC Drugs Sales Market Share by Application (2021-2026) Table 35. Global FIC Drugs Sales Market Share by Application (2027-2032) Table 36. Global FIC Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global FIC Drugs Revenue by Application (2021-2026) & (K Units) Table 38. Global FIC Drugs Revenue by Application (2027-2032) & (K Units) Table 39. Global FIC Drugs Revenue Market Share by Application (2021-2026) Table 40. Global FIC Drugs Revenue Market Share by Application (2027-2032) Table 41. Global FIC Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global FIC Drugs Sales by Region (2021-2026) & (K Units) Table 43. Global FIC Drugs Sales Market Share by Region (2021-2026) Table 44. Global FIC Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global FIC Drugs Sales Forecasted Market Share by Region (2027-2032) Table 46. North America FIC Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America FIC Drugs Sales by Country (2021-2026) & (K Units) Table 48. North America FIC Drugs Sales by Country (2027-2032) & (K Units) Table 49. Europe FIC Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe FIC Drugs Sales by Country (2021-2026) & (K Units) Table 51. Europe FIC Drugs Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific FIC Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific FIC Drugs Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific FIC Drugs Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa FIC Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa FIC Drugs Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa FIC Drugs Sales by Country (2027-2032) & (K Units) Table 58. Global FIC Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global FIC Drugs Revenue by Region (2021-2026) & (US$ Million) Table 60. Global FIC Drugs Revenue by Region (2027-2032) & (US$ Million) Table 61. Global FIC Drugs Revenue Market Share by Region (2021-2026) Table 62. Global FIC Drugs Revenue Market Share by Region (2027-2032) Table 63. Agios Company Information Table 64. Agios Business Overview Table 65. Agios FIC Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Agios FIC Drugs Product Portfolio Table 67. Agios Recent Development Table 68. BMS Company Information Table 69. BMS Business Overview Table 70. BMS FIC Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. BMS FIC Drugs Product Portfolio Table 72. BMS Recent Development Table 73. Boehringer Ingelheim Company Information Table 74. Boehringer Ingelheim Business Overview Table 75. Boehringer Ingelheim FIC Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Boehringer Ingelheim FIC Drugs Product Portfolio Table 77. Boehringer Ingelheim Recent Development Table 78. Dermavant Sciences Company Information Table 79. Dermavant Sciences Business Overview Table 80. Dermavant Sciences FIC Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Dermavant Sciences FIC Drugs Product Portfolio Table 82. Dermavant Sciences Recent Development Table 83. Genentech Company Information Table 84. Genentech Business Overview Table 85. Genentech FIC Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Genentech FIC Drugs Product Portfolio Table 87. Genentech Recent Development Table 88. Gilead Company Information Table 89. Gilead Business Overview Table 90. Gilead FIC Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Gilead FIC Drugs Product Portfolio Table 92. Gilead Recent Development Table 93. Immunocore Company Information Table 94. Immunocore Business Overview Table 95. Immunocore FIC Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Immunocore FIC Drugs Product Portfolio Table 97. Immunocore Recent Development Table 98. ImmunoGen Company Information Table 99. ImmunoGen Business Overview Table 100. ImmunoGen FIC Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. ImmunoGen FIC Drugs Product Portfolio Table 102. ImmunoGen Recent Development Table 103. Mallinckrodt Company Information Table 104. Mallinckrodt Business Overview Table 105. Mallinckrodt FIC Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Mallinckrodt FIC Drugs Product Portfolio Table 107. Mallinckrodt Recent Development Table 108. Marinus Company Information Table 109. Marinus Business Overview Table 110. Marinus FIC Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Marinus FIC Drugs Product Portfolio Table 112. Marinus Recent Development Table 113. Phathom Company Information Table 114. Phathom Business Overview Table 115. Phathom FIC Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Phathom FIC Drugs Product Portfolio Table 117. Phathom Recent Development Table 118. Polarean lmaging Company Information Table 119. Polarean lmaging Business Overview Table 120. Polarean lmaging FIC Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Polarean lmaging FIC Drugs Product Portfolio Table 122. Polarean lmaging Recent Development Table 123. Pfizer Company Information Table 124. Pfizer Business Overview Table 125. Pfizer FIC Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Pfizer FIC Drugs Product Portfolio Table 127. Pfizer Recent Development Table 128. Eli Lilly Company Information Table 129. Eli Lilly Business Overview Table 130. Eli Lilly FIC Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. Eli Lilly FIC Drugs Product Portfolio Table 132. Eli Lilly Recent Development Table 133. Roche Company Information Table 134. Roche Business Overview Table 135. Roche FIC Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 136. Roche FIC Drugs Product Portfolio Table 137. Roche Recent Development Table 138. Merck Company Information Table 139. Merck Business Overview Table 140. Merck FIC Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 141. Merck FIC Drugs Product Portfolio Table 142. Merck Recent Development Table 143. Novartis Company Information Table 144. Novartis Business Overview Table 145. Novartis FIC Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 146. Novartis FIC Drugs Product Portfolio Table 147. Novartis Recent Development Table 148. Johnson & Johnson Company Information Table 149. Johnson & Johnson Business Overview Table 150. Johnson & Johnson FIC Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 151. Johnson & Johnson FIC Drugs Product Portfolio Table 152. Johnson & Johnson Recent Development Table 153. Sanofi Company Information Table 154. Sanofi Business Overview Table 155. Sanofi FIC Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 156. Sanofi FIC Drugs Product Portfolio Table 157. Sanofi Recent Development Table 158. Key Raw Materials Table 159. Raw Materials Key Suppliers Table 160. FIC Drugs Distributors List Table 161. FIC Drugs Customers List Table 162. Research Programs/Design for This Report Table 163. Authors List of This Report Table 164. Secondary Sources Table 165. Primary Sources List of Figures Figure 1. FIC Drugs Product Image Figure 2. Global FIC Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global FIC Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global FIC Drugs Sales (2021-2032) & (K Units) Figure 5. Global FIC Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 FIC Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. FIC Single-target Drugs Image Figure 9. FIC Dual-target Drugs Image Figure 10. Global FIC Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global FIC Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global FIC Drugs Sales Market Share by Type (2021-2032) Figure 13. Global FIC Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global FIC Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global FIC Drugs Revenue Market Share by Type (2021-2032) Figure 16. Hospital Image Figure 17. Clinic Image Figure 18. Other Image Figure 19. Global FIC Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global FIC Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global FIC Drugs Sales Market Share by Application (2021-2032) Figure 22. Global FIC Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global FIC Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global FIC Drugs Revenue Market Share by Application (2021-2032) Figure 25. North America FIC Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America FIC Drugs Sales Market Share by Country (2021-2032) Figure 27. U.S. FIC Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada FIC Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico FIC Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe FIC Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe FIC Drugs Sales Market Share by Country (2021-2032) Figure 32. Germany FIC Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France FIC Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. FIC Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy FIC Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands FIC Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific FIC Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific FIC Drugs Sales Market Share by Country (2021-2032) Figure 39. China FIC Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan FIC Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea FIC Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia FIC Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India FIC Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia FIC Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa FIC Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa FIC Drugs Sales Market Share by Country (2021-2032) Figure 47. Brazil FIC Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa FIC Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia FIC Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey FIC Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina FIC Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE FIC Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt FIC Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile FIC Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global FIC Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global FIC Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America FIC Drugs Revenue (2021-2032) & (US$ Million) Figure 58. North America FIC Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe FIC Drugs Revenue (2021-2032) & (US$ Million) Figure 60. Europe FIC Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific FIC Drugs Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific FIC Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa FIC Drugs Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa FIC Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. FIC Drugs Value Chain Figure 66. Manufacturing Cost Structure Figure 67. FIC Drugs Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • FIC Single-target Drugs
  • FIC Dual-target Drugs
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Agios
  • BMS
  • Boehringer Ingelheim
  • Dermavant Sciences
  • Genentech
  • Gilead
  • Immunocore
  • ImmunoGen
  • Mallinckrodt
  • Marinus
  • Phathom
  • Polarean lmaging
  • Pfizer
  • Eli Lilly
  • Roche
  • Merck
  • Novartis
  • Johnson & Johnson
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global FIC Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global FIC Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global FIC Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global FIC Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global FIC Drugs Market Dynamics
  1. 2.1 FIC Drugs Industry Trends
  2. 2.2 FIC Drugs Industry Drivers
  3. 2.3 FIC Drugs Industry Opportunities and Challenges
  4. 2.4 FIC Drugs Industry Restraints
3 FIC Drugs Market by Manufacturers
  1. 3.1 Global FIC Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global FIC Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global FIC Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global FIC Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global FIC Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global FIC Drugs Manufacturers, Product Type & Application
  7. 3.7 Global FIC Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global FIC Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 FIC Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 FIC Drugs Tier 1, Tier 2, and Tier 3
4 FIC Drugs Market by Type
  1. 4.1 FIC Drugs Type Introduction
  2. 4.1.1 FIC Single-target Drugs
  3. 4.1.2 FIC Dual-target Drugs
  4. 4.2 Global FIC Drugs Sales by Type
  5. 4.2.1 Global FIC Drugs Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global FIC Drugs Sales by Type (2021-2032)
  7. 4.2.3 Global FIC Drugs Sales Market Share by Type (2021-2032)
  8. 4.3 Global FIC Drugs Revenue by Type
  9. 4.3.1 Global FIC Drugs Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global FIC Drugs Revenue by Type (2021-2032)
  11. 4.3.3 Global FIC Drugs Revenue Market Share by Type (2021-2032)
5 FIC Drugs Market by Application
  1. 5.1 FIC Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global FIC Drugs Sales by Application
  6. 5.2.1 Global FIC Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global FIC Drugs Sales by Application (2021-2032)
  8. 5.2.3 Global FIC Drugs Sales Market Share by Application (2021-2032)
  9. 5.3 Global FIC Drugs Revenue by Application
  10. 5.3.1 Global FIC Drugs Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global FIC Drugs Revenue by Application (2021-2032)
  12. 5.3.3 Global FIC Drugs Revenue Market Share by Application (2021-2032)
6 Global FIC Drugs Sales by Region
  1. 6.1 Global FIC Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global FIC Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global FIC Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global FIC Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America FIC Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America FIC Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe FIC Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe FIC Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific FIC Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific FIC Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa FIC Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa FIC Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global FIC Drugs Revenue by Region
  1. 7.1 Global FIC Drugs Revenue by Region
  2. 7.1.1 Global FIC Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global FIC Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global FIC Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global FIC Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America FIC Drugs Revenue (2021-2032)
  8. 7.2.2 North America FIC Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe FIC Drugs Revenue (2021-2032)
  11. 7.3.2 Europe FIC Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific FIC Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific FIC Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa FIC Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa FIC Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Agios
  2. 8.1.1 Agios Company Information
  3. 8.1.2 Agios Business Overview
  4. 8.1.3 Agios FIC Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Agios FIC Drugs Product Portfolio
  6. 8.1.5 Agios Recent Developments
  7. 8.2 BMS
  8. 8.2.1 BMS Company Information
  9. 8.2.2 BMS Business Overview
  10. 8.2.3 BMS FIC Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 BMS FIC Drugs Product Portfolio
  12. 8.2.5 BMS Recent Developments
  13. 8.3 Boehringer Ingelheim
  14. 8.3.1 Boehringer Ingelheim Company Information
  15. 8.3.2 Boehringer Ingelheim Business Overview
  16. 8.3.3 Boehringer Ingelheim FIC Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Boehringer Ingelheim FIC Drugs Product Portfolio
  18. 8.3.5 Boehringer Ingelheim Recent Developments
  19. 8.4 Dermavant Sciences
  20. 8.4.1 Dermavant Sciences Company Information
  21. 8.4.2 Dermavant Sciences Business Overview
  22. 8.4.3 Dermavant Sciences FIC Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Dermavant Sciences FIC Drugs Product Portfolio
  24. 8.4.5 Dermavant Sciences Recent Developments
  25. 8.5 Genentech
  26. 8.5.1 Genentech Company Information
  27. 8.5.2 Genentech Business Overview
  28. 8.5.3 Genentech FIC Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Genentech FIC Drugs Product Portfolio
  30. 8.5.5 Genentech Recent Developments
  31. 8.6 Gilead
  32. 8.6.1 Gilead Company Information
  33. 8.6.2 Gilead Business Overview
  34. 8.6.3 Gilead FIC Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Gilead FIC Drugs Product Portfolio
  36. 8.6.5 Gilead Recent Developments
  37. 8.7 Immunocore
  38. 8.7.1 Immunocore Company Information
  39. 8.7.2 Immunocore Business Overview
  40. 8.7.3 Immunocore FIC Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Immunocore FIC Drugs Product Portfolio
  42. 8.7.5 Immunocore Recent Developments
  43. 8.8 ImmunoGen
  44. 8.8.1 ImmunoGen Company Information
  45. 8.8.2 ImmunoGen Business Overview
  46. 8.8.3 ImmunoGen FIC Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 ImmunoGen FIC Drugs Product Portfolio
  48. 8.8.5 ImmunoGen Recent Developments
  49. 8.9 Mallinckrodt
  50. 8.9.1 Mallinckrodt Company Information
  51. 8.9.2 Mallinckrodt Business Overview
  52. 8.9.3 Mallinckrodt FIC Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Mallinckrodt FIC Drugs Product Portfolio
  54. 8.9.5 Mallinckrodt Recent Developments
  55. 8.10 Marinus
  56. 8.10.1 Marinus Company Information
  57. 8.10.2 Marinus Business Overview
  58. 8.10.3 Marinus FIC Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Marinus FIC Drugs Product Portfolio
  60. 8.10.5 Marinus Recent Developments
  61. 8.11 Phathom
  62. 8.11.1 Phathom Company Information
  63. 8.11.2 Phathom Business Overview
  64. 8.11.3 Phathom FIC Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Phathom FIC Drugs Product Portfolio
  66. 8.11.5 Phathom Recent Developments
  67. 8.12 Polarean lmaging
  68. 8.12.1 Polarean lmaging Company Information
  69. 8.12.2 Polarean lmaging Business Overview
  70. 8.12.3 Polarean lmaging FIC Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Polarean lmaging FIC Drugs Product Portfolio
  72. 8.12.5 Polarean lmaging Recent Developments
  73. 8.13 Pfizer
  74. 8.13.1 Pfizer Company Information
  75. 8.13.2 Pfizer Business Overview
  76. 8.13.3 Pfizer FIC Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Pfizer FIC Drugs Product Portfolio
  78. 8.13.5 Pfizer Recent Developments
  79. 8.14 Eli Lilly
  80. 8.14.1 Eli Lilly Company Information
  81. 8.14.2 Eli Lilly Business Overview
  82. 8.14.3 Eli Lilly FIC Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Eli Lilly FIC Drugs Product Portfolio
  84. 8.14.5 Eli Lilly Recent Developments
  85. 8.15 Roche
  86. 8.15.1 Roche Company Information
  87. 8.15.2 Roche Business Overview
  88. 8.15.3 Roche FIC Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Roche FIC Drugs Product Portfolio
  90. 8.15.5 Roche Recent Developments
  91. 8.16 Merck
  92. 8.16.1 Merck Company Information
  93. 8.16.2 Merck Business Overview
  94. 8.16.3 Merck FIC Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Merck FIC Drugs Product Portfolio
  96. 8.16.5 Merck Recent Developments
  97. 8.17 Novartis
  98. 8.17.1 Novartis Company Information
  99. 8.17.2 Novartis Business Overview
  100. 8.17.3 Novartis FIC Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Novartis FIC Drugs Product Portfolio
  102. 8.17.5 Novartis Recent Developments
  103. 8.18 Johnson & Johnson
  104. 8.18.1 Johnson & Johnson Company Information
  105. 8.18.2 Johnson & Johnson Business Overview
  106. 8.18.3 Johnson & Johnson FIC Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Johnson & Johnson FIC Drugs Product Portfolio
  108. 8.18.5 Johnson & Johnson Recent Developments
  109. 8.19 Sanofi
  110. 8.19.1 Sanofi Company Information
  111. 8.19.2 Sanofi Business Overview
  112. 8.19.3 Sanofi FIC Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Sanofi FIC Drugs Product Portfolio
  114. 8.19.5 Sanofi Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 FIC Drugs Value Chain Analysis
  2. 9.1.1 FIC Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 FIC Drugs Production Mode & Process
  6. 9.2 FIC Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 FIC Drugs Distributors
  9. 9.2.3 FIC Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst